Keratoendotheliitis fugax hereditaria

Lore & Background

Keratoendotheliitis fugax hereditaria was first described in 1964 by Finnish ophthalmologist Olavi Valle, who reported it as keratitis fugax hereditaria in a family with 10 affected members over 4 generations. Two decades later, a second Finnish family with 21 affected members in 5 generations was reported by other Finnish ophthalmologists, who highlighted transient corneal endothelial changes and proposed the current name. The disease has only been described from Finland, but exome databases indicate the mutation may be present in non-Finnish European populations at a low frequency.

Reader's Guide

Keratoendotheliitis fugax hereditaria is significant as a rare, autosomal dominant corneal disorder linked to the NLRP3 gene and cryopyrin-associated periodic syndromes. Its presentation—unilateral attacks of keratitis with pseudoguttae, redness, pain, and photophobia—can be misdiagnosed as acute iridocyclitis. The disease typically begins between ages 5 and 28, with attacks 1 to 6 times per year that decrease in severity and frequency by middle age. Diagnosis relies on identifying corneal pseudoguttata via specular or confocal microscopy, with molecular genetic testing available. Treatment involves topical corticosteroids or NSAIDs, with some patients benefiting from oral NSAIDs. Over time, repeated inflammation can reduce visual acuity, though central stromal opacities have not required corneal transplantation. The condition underscores the importance of genetic and clinical awareness in diagnosing hereditary corneal diseases, particularly in populations of European ancestry.

Did You Know?

• The disease is caused by a point mutation in cryopyrin, encoded by the NLRP3 gene on the long arm of chromosome 1.
• Attacks occur 1 to 6 times per year, beginning between ages 5 and 28, and become less severe in middle age.
• The common mutation D21H accounts for all reported cases in the Finnish population.

Clinical Manifestations and Diagnostic Pathways

Patients with this rare corneal condition experience recurrent unilateral episodes of keratitis, typically occurring one to six times annually, with onset between ages five and twenty-eight. Both sexes are equally susceptible, and no seasonal pattern has been identified. Each flare presents with eye redness, pain, and sensitivity to light, sometimes accompanied by anterior chamber flare. The acute symptoms resolve within one to two days, though blurred vision can persist for several weeks. Under slit-lamp examination during an attack, clinicians observe pseudoguttae—dark patches in the corneal endothelium interpreted as focal endothelial swelling—while the endothelium appears entirely normal between episodes. Because the presentation can mimic acute iridocyclitis, misdiagnosis is a recognized risk. In older individuals, repeated inflammation may leave faint to definite central, horizontally oval stromal opacities in both eyes. Diagnosis relies on specular or confocal microscopy to document pseudoguttata, supplemented by molecular genetic testing when available. Roughly fifty cases have been documented in the medical literature to date.

Genetic Basis and Population Distribution

The condition follows an autosomal dominant inheritance pattern, requiring only a single mutated allele to produce disease. The underlying defect is a point mutation in the cryopyrin protein, encoded by the NLRP3 gene situated at position 1q44 on the long arm of chromosome one. Because of this genetic link, the disorder is classified within the broader family of cryopyrin-associated periodic syndromes. All Finnish cases reported to date carry a specific D21H substitution, making it the sole mutation identified in that population. The disease has not been formally described outside Finland, yet exome database analyses reveal the D21H variant at a minor allele frequency of 0.023 percent among Finns and 0.0090 percent in aggregated non-Finnish European cohorts. These figures suggest the mutation—and potentially the disease—may be more broadly distributed among people of European descent than previously recognized, even though clinical reports remain confined to a single country.

Discovery and Nomenclature

The condition entered the medical literature in 1964 through the work of Olavi Valle, a Finnish ophthalmologist (1934–2013) whose research focus included hereditary eye diseases. Valle described the entity as keratitis fugax hereditaria after examining a single Finnish family in which ten members across four generations were affected. For nearly two decades the condition remained a curiosity limited to that one pedigree. The turning point came around 1984, when a second Finnish family—this one with twenty-one affected individuals spanning five generations—was reported by a different group of Finnish ophthalmologists. Their detailed observations emphasized the transient corneal endothelial changes that distinguish the disease from other forms of recurrent keratitis. Recognizing the endothelial involvement as a defining feature, these researchers proposed the more precise name keratoendotheliitis fugax hereditaria, a designation that has endured and now anchors the condition's identity in the ophthalmic literature.

Management and Long-Term Outlook

Because attacks are self-limiting, treatment is aimed at relieving symptoms during each episode rather than preventing them. Patients have reported meaningful benefit from applying a topical corticosteroid or a non-steroidal anti-inflammatory drug several times daily for up to one week at the onset of a flare. Some individuals find greater relief with an oral NSAID instead. Importantly, the severity and frequency of attacks tend to diminish in middle age, and no seasonal trigger has been identified. The principal long-term concern is cumulative damage: repeated episodes of corneal inflammation can gradually reduce visual acuity, and in some patients the repeated insults produce central stromal opacities. However, even when these opacities are definite, they have not been severe enough to necessitate corneal transplantation. The endothelium between attacks appears normal, and the overall trajectory—mild, episodic, and progressively less troublesome with age—suggests a manageable condition, though the small number of documented cases limits the strength of long-term prognostic data.